Accure Therapeutics, of Barcelona, Spain, said it launched with a series A round of funding totaling €7.6 million (US$8.1 million). The funding round was led by Alta Life Sciences and supported by the Centre for Technological and Industrial Development. The company will develop a portfolio of new drug candidates to treat CNS diseases. It said it will start work on three distinct new medicine programs focused on innovative targets (POP, MMP and IGF1).

Arvelle Therapeutics GmbH, of Zug, Switzerland, an emerging biopharmaceutical company focused on bringing innovative treatments to patients with CNS disorders, said it closed the final tranche of its series A financing round of $42.7 million, triggered by the EMA’s acceptance of the marketing authorization application for cenobamate for the adjunctive treatment of focal-onset seizures in adults with epilepsy. The total capital raised in the round was $207.8 million.

Avidity Biosciences Inc., of La Jolla, Calif., has filed to raise up to $100 million in an IPO and applied to list its shares on Nasdaq under the symbol RNA. It is developing antibody-oligonucleotide conjugates (AOCs), a new class of oligonucleotide-based therapies, to treat a wide range of diseases. Lead product candidate, AOC-1001, is designed to treat myotonic dystrophy type 1, and the company said it plans to submit an IND for the compound in 2021. Other AOC product candidates are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease.

Biolinerx Ltd., of Tel Aviv, Israel, said it entered definitive agreements with several health care-focused, institutional and accredited investors for the purchase and sale of 5.14 million of its American depositary shares (ADSs) at $1.75 each, in a registered direct offering. In a concurrent private placement, the investors will receive unregistered warrants, with an exercise price of $2.25 per ADS, to purchase up to an aggregate of 5.14 million ADSs. The gross proceeds are expected to be $9 million, and the net proceeds will be used for general corporate purposes.

Gamida Cell Ltd., of Boston, said the underwriters of its public offering have exercised in full their option to purchase an additional 2 million of its ordinary shares at $4.50 each. That brings the total number of shares sold by the company in the offering to 15.33 million shares, resulting in aggregate gross proceeds of approximately $69 million.

Generation Bio Co., of Cambridge, Mass., has filed to raise up to $125 million in an IPO and expects its shares will trade on Nasdaq under the symbol GBIO. The genetic medicines company disclosed in its prospectus that it is using a cell-targeted lipid nanoparticle delivery system and a scalable capsid-free manufacturing process. The technologies will support the advancement of a product portfolio including eight programs for rare and prevalent diseases of the liver and retina.

Insitro Inc., of South San Francisco, said it raised $143 million in an oversubscribed series B financing led by Andreessen Horowitz, with participation from new investors Canada Pension Plan Investment Board and funds and accounts advised by T. Rowe Price Associates Inc. as well as funds managed by Blackrock, Casdin Capital, HOF Capital, Wuxi Apptec’s Corporate Venture Fund and other undisclosed investors. Current investors Arch Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures and Alexandria Venture Investments also participated in the financing. The funds support data generation at larger scale and expansion of its capabilities to generate predictive models of human disease. In addition, the capital will be used to prosecute newly identified, genetically validated targets, to identify patient segmentation biomarkers, and to advance therapeutics in genetically defined patient populations.

Nanoviricides Inc., of Shelton, Conn., said it raised $10.22 million in gross proceeds from the sale of 1.4 million shares of common stock, and no warrants, at a price of $7.30 per share. The company intends to use the net proceeds for general business purposes.

OSE Immunotherapeutics SA, of Nantes, France, said it negotiated a €7 million (US$7.68 million) nondilutive loan agreement, with a pool of French banks, providing the company with further financing to advance its clinical and preclinical development programs. The loan is part of a loan facility guaranteed by the French State and was implemented in the context of the COVID-19 pandemic.

Portage Biotech Inc., of Toronto, said that, in addition to completing its reverse stock split, it will be conducting a nonbrokered private placement of post-consolidation common shares for gross proceeds of up to $10 million at $10 per post-consolidated common share. The net proceeds will be used for further development of its immune-oncology portfolio toward clinical testing; the formation of one to two new companies; and to pursue an additional listing of its common shares on a senior stock exchange.

Poxel SA, of Lyon, France, said it completed a private placement of 2.35 million new ordinary shares for gross proceeds of €17.68 million (US$19.4 million). The funding will enable the company to accelerate its development plans for PXL-770 and PXL-065 for the treatment of nonalcoholic steatohepatitis, and to pursue development activities in other metabolic diseases and for general corporate purposes. In addition, the company placed 1.76 million warrants with a five-year term attached to the new shares and a strike price of €10.03.

Preveceutical Medical Inc., of Vancouver, British Columbia, said it entered a shares-for-debt settlement with arm’s length creditors for a full and final payment of $198,805.82. To settle the debt, Preveceutical issued about 95.6 million common shares without par value in its capital at 23 cents per share. Preveceutical is developing a water-based cannabidiol sol-gel formulation and nasal applicator to reduce the possibility of coronavirus infections.

Sterna Biologicals GmbH & Co. KG, of Marburg, Germany, said it secured €12 million (US$13 million) in a private placement to fund a phase II trial with SB-010 in moderate to severe asthma, the development of an oral formulation for SB-012 to treat moderate to severe ulcerative colitis, and related chemistry, manufacturing and controls activities. The broad-spectrum topicals are designed to treat type 2 inflammatory diseases.

Tollys SAS, of Lyon, France, said it closed a series A financing of €2.3 million (US$2.5 million), bringing the total amount raised to €6.4 million since the company’s 2015 founding. Current shareholders and new private investors joined the round. Proceeds will be used to advance the preclinical development of TL-532, a TLR3 agonist, including regulatory safety studies required before entry into clinical trials in bladder cancer by late 2021 or early 2022.

Tricida Inc., of South San Francisco, said it closed an offering of $200 million aggregate principal amount of its 3.5% convertible senior notes due 2027 in a private offering to institutional buyers. Tricida estimated net proceeds will be about $193 million. Tricida said it intends to use the money for working capital and general corporate purposes. The company is developing TRC-101 (veverimer), a non-absorbed, orally administered polymer to treat metabolic acidosis chronic kidney disease patients.

Windtree Therapeutics Inc., of Warrington, Pa., said it closed its public offering of about 2.8 million units at a price to the public of $7.25 per unit. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $7.975 per share. The warrants are exercisable for five years from the date of issuance. Windtree received net proceeds of about $20.2 million and its common stock began trading on Nasdaq on May 20 under the symbol WINT. Windtree intends to use the net proceeds to advance the study of KL4 surfactant to treat COVID-19-related lung injury, istaroxime acute heart failure phase IIb startup activities, clinical development of Aerosurf for respiratory distress syndrome, preclinical studies of oral SERCA2a activators, and for working capital and/or general corporate purposes.

No Comments